Table 1.
Clinical trials for assessing the oncolytic adenovirus and Herpes Simplex Virus therapy effect in patients suffering from pancreatic cancer.
| Phase | Oncolytic virus | Site of Admin | Combined with | No of Patients | Patients’ Info | Year | mPFS (Months) | mOS (Months) | Study |
|---|---|---|---|---|---|---|---|---|---|
| Adenovirus | |||||||||
| I | AdV-tk | Intratumoral injection | Valacyclovir | 27 | Arm A: Resectable Arm B: unresectable LAPC |
Start: 2008 End: 2015 |
Arm A: - Arm B: 5.8 |
Arm A: 11 Arm B: 12 |
(NCT00638612) (133) |
| I | (Ad5-DS) | Intratumoral injection | 5- Fluorocytosine /Valganciclovir /Standard dose of intravenous Gemcitabine |
9 | LAPC | Start: 2016 End: 2019 |
11.4 | – | (NCT00638612) (133) |
| I | (Ad5-DS) | – | 5-fluorocytosine/ valganciclovir |
8 | Non-metastatic LAPC |
Start: 2006 Terminated (Poor enrollment) |
– | – | (NCT00415454) |
| I | CAdVEC | Intratumoral injection | – | 45 Patients with 10 different malignances |
LAPC | Start: 2020 End: 2038 |
– | – | (NCT03740256) |
| I, II | LOAd703 | Intratumoral injection | – | 50 Patients with 4 different malignances |
LAPC | Start: 2018 End: 2022 |
– | – | (NCT03225989) |
| Herpes Simplex Virus | |||||||||
| I | HF10 (HSV) | Intratumoral injection | Erlotinib/Gemcitabine | 10 | Unresectable LAPC |
Study End: 2018 |
6.3 | 15.5 | (152) |
| I, II | OH2 | Intratumoral injection | – | 25 | LAPC or metastatic | Start: 2021 End: 2022 |
– | – | (NCT04637698) |
| I | T-VEC | Intratumoral injection | – | 16 | LAPC or metastatic |
Start: 2017 End: 2026 |
– | – | (NCT03086642) (NCT03252808) |
| I | HF10 (HSV) | Intratumoral injection | Gemcitabine/ Nab-paclitaxel/ TS-1 |
36 | LAPC and never received anticancer therapy |
Start: 2017 End: 2035 |
– | – | (153) |
| I | HF10 (HSV) | Intratumoral injection | – | Total: 17 8 pancreatic cancer patients |
Unresectable LAPC | Start: 2006 End: 2014 |
– | – | (154) |
| I | HF10 (HSV) | Intratumoral injection | – | Total: 9 3 pancreatic cancer patients |
LAPC and metastatic | Start: 2005 End: 2007 |
– | – | (155) |